Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE: NVO ) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE: LLY ) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trials, and market expansion.

Novo Nordisk A/S (NYSE:NVO)'s legal action centers on commercial advertisements aired during major broadcasts and social media platforms. Novo Nordisk claims that Eli Lilly's promotional campaigns intentionally use outdated trial data to pit the highest approved doses of Lilly's tirzepatide (Zepbound/Mounjaro) against lower, older doses of Novo's semaglutide (Wegovy/Ozempic). Novo argues these ads create consumer confusion by omitting Novo's recently approved higher-dose versions, demanding a permanent injunction to pull the ads and force Lilly to launch a corrective campaign.

Eli Lilly and Company (NYSE:LLY) fired back immediately, stating that its commercials are "truthful," "transparent," and grounded in direct scientific evidence. A spokesperson for Eli Lilly emphasized that the claims stem from the SURMOUNT-5 trial, which is a rigorous head-to-head clinical study directly comparing tirzepatide against semaglutide. Lilly asserted that rather than competing on product merits, Novo Nordisk is attempting to censor published trial results. Lilly confirmed it plans to defend itself "vigorously" in court.

Both companies remain highly profitable, but Eli Lilly is currently demonstrating significantly faster top-line growth and stronger forward momentum based on their Q1 2026 financial results.

Eli Lilly delivered exceptional growth in its Q1 2026 results, with revenue increasing 56% year-over-year to $19.8 billion. The growth was primarily driven by a 65% increase in sales volume, led by strong demand for its blockbuster GLP-1 medicines, Mounjaro and Zepbound.

The company also reported a significant improvement in profitability, with net income reaching $7.4 billion, or $8.26 per share, compared with $2.8 billion, or $3.06 per share, in Q1 2025. Non-GAAP EPS surged 156% to $8.55, reflecting strong operating leverage and robust commercial execution.

Supported by accelerating demand, Eli Lilly raised its full-year 2026 revenue guidance by $2 billion, increasing its expected revenue range to $82.0 billion–$85.0 billion. The company also lifted its non-GAAP EPS outlook to $35.50–$37.00, signaling continued confidence in its growth trajectory.

Novo Nordisk delivered solid headline growth in Q1 2026, but its results reflected a more complex operating environment. Net sales increased 32% year-over-year in constant exchange rates (CER) to DKK 96.82 billion ($13.8 billion). However, this growth was significantly impacted by a $4.2 billion non-recurring provision reversal related to the U.S. 340B Drug Pricing Program. Excluding this one-time benefit, adjusted sales declined 4% at CER due to lower realized prices in the U.S., despite continued volume growth in GLP-1 products.